Fig. 3: Recurrence rates based on the postoperative evaluation of serum NY-ESO-1 antibody responses.

Kaplan–Meier analysis of cumulative recurrence rates was assessed based on the NY-ESO-1 antibody status at 12 months (a) and 3 months (b) after surgery. HRs and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test. Percentages of patients with or without recurrence based on NY-ESO-1 antibody status at 12 months (c) and 3 months (d) after surgery. P values were calculated using a two-sided chi-squared test comparing the distribution of factors between the two columns (positive vs negative). The sensitivity and specificity for postoperative recurrence assessed by NY-ESO-1 positivity are shown below the graph.